Harmony Biosciences Holdings, Inc. (HRMY)
| Market Cap | 2.35B +50.7% |
| Revenue (ttm) | 959.90M +24.3% |
| Net Income | 181.27M +0.2% |
| EPS | 3.09 -0.1% |
| Shares Out | 58.24M |
| PE Ratio | 13.03 |
| Forward PE | 10.06 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 487,061 |
| Open | 39.53 |
| Previous Close | 39.60 |
| Day's Range | 39.51 - 40.57 |
| 52-Week Range | 25.52 - 43.49 |
| Beta | 1.01 |
| Analysts | Buy |
| Price Target | 47.64 (+18.27%) |
| Est. Earnings | Nov 3, 2026 |
About HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in P... [Read more]
Financial Performance
In 2025, HRMY's revenue was $868.45 million, an increase of 21.51% compared to the previous year's $714.73 million. Earnings were $158.69 million, an increase of 9.07%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for HRMY stock is "Buy." The 12-month stock price target is $47.64, which is an increase of 18.27% from the latest price.
News
Harmony Biosciences price target raised to $42 from $39 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Harmony Biosciences (HRMY) to $42 from $39 and keeps a Hold rating on the shares after hosting a virtual non-deal roadshow management.
Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days
PLYMOUTH MEETING, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present a poster featuring information from its ongoing Phase 3 ...
Harmony Biosciences Holdings Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Management outlined a strategy focused on expanding the pipeline with BP-205 and other orexin-2 agonists, targeting both sleep and broader CNS indications. Business development remains a top priority, with multiple deals expected to bridge revenue post-2028, while robust IP defense aims to maintain WAKIX exclusivity through 2030.
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress
PLYMOUTH MEETING, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore data from the company's investigation of EPX-100...
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 20...
Harmony Biosciences initiated with an Outperform at Wolfe Research
Wolfe Research analyst Rudy Li initiated coverage of Harmony Biosciences (HRMY) with an Outperform rating and $60 price target The firm believes the company’s Wakix base business of can justify…
Harmony Biosciences Holdings Transcript: Piper Sandler Virtual CNS Symposium
Record WAKIX sales are fueling pipeline growth, including BP-205, a potent orexin agonist advancing toward multiple CNS indications. Clemizole shows promise in epilepsy with strong efficacy and safety, while new pitolisant formulations aim to expand market reach and address unmet needs.
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Pi...
Harmony Biosciences price target raised to $34 from $29 at Truist
Truist analyst Danielle Brill raised the firm’s price target on Harmony Biosciences (HRMY) to $34 from $29 and keeps a Hold rating on the shares.
Harmony Biosciences price target raised to $39 from $36 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Harmony Biosciences (HRMY) to $39 from $36 and keeps a Hold rating on the shares.
Harmony Biosciences price target raised to $37 from $33 at UBS
UBS raised the firm’s price target on Harmony Biosciences (HRMY) to $37 from $33 and keeps a Neutral rating on the shares. Shares gained on encouraging initial BP-205 human data,…
Harmony Biosciences price target raised to $30 from $28 at BofA
BofA analyst Jason Gerberry raised the firm’s price target on Harmony Biosciences (HRMY) to $30 from $28 and keeps an Underperform rating on the shares. The firm’s raised target reflects…
Harmony Biosciences Holdings Earnings Call Transcript: Q2 2026
Record Q2 revenue of $261.3M (up 30% YoY) and strong net income reflect robust WAKIX demand and effective expense management. BP-205 advanced with positive phase I data, and multiple data catalysts are expected in the next six months. Cash reserves of $963M support ongoing growth and business development.
Harmony Biosciences Holdings Earnings release: Q2 2026
Harmony Biosciences Holdings released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Harmony Biosciences Holdings Slides: Q2 2026
Harmony Biosciences Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Harmony Biosciences Holdings Quarterly report: Q2 2026
Harmony Biosciences Holdings has published its Q2 2026 quarterly earnings report on August 4, 2026.
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
WAKIX® Net Revenue Grew 30% Year over Year to $261.3 Million for Second Quarter 2026; Estimated Average Patients Increased 450 to 8,950; Reiterates 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $...
Harmony Biosciences price target raised to $51 from $50 at Mizuho
Mizuho raised the firm’s price target on Harmony Biosciences (HRMY) to $51 from $50 and keeps an Outperform rating on the shares. The firm updated models in the smid-cap biotechnology…
Harmony Biosciences price target raised to $51 from $50 at Mizuho
Mizuho raised the firm’s price target on Harmony Biosciences (HRMY) to $51 from $50 and keeps an Outperform rating on the shares.
Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
PLYMOUTH MEETING, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2026 financial results on Tuesday, August ...
Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of appr...
Harmony Biosciences price target raised to $36 from $30 at Deutsche Bank
Deutsche Bank analyst David Hoang raised the firm’s price target on Harmony Biosciences (HRMY) to $36 from $30 and keeps a Hold rating on the shares. The firm cites a…
20 growth stocks priced as value stocks
A broad screen of U.S. stocks yields a list of companies trading at low valuations to expected earnings, with high projected revenue growth rates through 2028. The list of 20 stocks includes eight fin...
Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster pre...
Harmony Biosciences Holdings Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Management outlined a four-pillar strategy: protecting IP, growing WAKIX, advancing the orexin pipeline, and targeted business development. WAKIX is set for blockbuster status, with new GR and HD formulations extending its lifecycle. BP-205 orexin agonist is advancing in the clinic, with broader CNS indications targeted.